PRIMAVERA
Start Date:
November 2021
End Date:
ongoing
Duration:
60 months
ID-CARE Role:
Website:
Partner
Description
GA Number: 101034420
Title: PrIMAVeRa - Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance
Primary Objectives: The goal of PrIMAVeRa is to develop comprehensive mathematical models to predict the impact of vaccines and monoclonal antibodies (mAbs) on the reduction of antimicrobial resistance (AMR), thereby enabling decision-makers to prioritise the most promising new vaccines and mAbs.
A sustainability plan will also be designed by the project partners with the goal to ensure long-term access to the project results, including models, beyond the duration of the PrIMAVeRa project.
The following main goals will be addressed in an integrated manner:
Assessment of the availability and quality of published data and existing mathematical models of AMR
Setting up a comprehensive epidemiological repository
Development of improved mathematical models of AMR including cost-effectiveness analyses (CEA)
Establishment of a plan for evaluation
Partners
Ares Genetics GmbH - AUSTRIA
Danmarks Tekniske Universitet - DENMARK
Eberhard Karls Universität Tübingen - DENMARK
European Vaccine Initiative (EVI) - DENMARK
GlaxoSmithKline Biologicals SA (GSK) - BELGIUM
Hospital of Lithuanian University of Health Sciences Kauno Klinikos - LITHUANIA
Institut Pasteur - FRANCE
Institute of Health Carlos III - SPAIN
Janssen Vaccines & Prevention B.V. - NETHERLANDS
Life Science Network gGmbH - DENMARK
Pasteur Institute of Russia - RUSSIA
Pfizer - UK
Public Health England - UK
Servicio Andaluz de Salud - SPAIN
Université Grenoble Alpes - FRANCE
University Medical Center Utrecht (UMC Utrecht) - NETHERLANDS
University of Geneva - SWITZERLAND
University of Oxford - UK
Sponsor
